The MEASUREme™ Resource Module includes recently published key references that are cited throughout the slide sections.

Akiskal HS. Searching for behavioral indicators of bipolar II in patients presenting with major depressive episodes: the “red sign,” the “rule of three” and other biographic signs of temperamental extravagance, activation and hypomania. J Affect Disord. 2005;84:279-290.

Akiskal HS. The bipolar spectrum-the shaping of a new paradigm in psychiatry. Curr Psychiatry Rep. 2002;4:1-3.

Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord. 2005;85:245-258.

Akiskal HS, Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, IV. Psychiatr Clin North Am. 1999;22:517-534.

Altshuler LL, Post RM, Black DO, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry. 2006;67:1551-1560.

Altshuler LL, Suppes T, Black DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry. 2006;163:313-315.

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.

American Psychiatric Association. Practice Guideline for the Treatment of Patients with Bipolar Disorder. 2nd ed. Washington, DC; 2002.

American Psychiatric Association. Practice Guideline For the Treatment of Patients with Bipolar Disorder, Text revision. Am J Psychiatry. 2002;159(suppl 4):1-50.

Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rossler W. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord. 2003;73:133-146.

Benazzi F. Mixed states in bipolar II disorder: should full hypomania always be required? Psychiatry Res. 2004;127:247-257.

Berk M, Berk L, Moss K, Dodd S, Malhi GS. Diagnosing bipolar disorder: how can we do it better? Med J Aust. 2006;184:459-462.

Berk M, Dodd S, Malhi GS. ‘Bipolar missed states’: the diagnosis and clinical salience of bipolar mixed states. Aust N Z J Psychiatry. 2005;39:215-221.

Blehar MC, DePaulo JR Jr, Gershon ES, Reich T, Simpson SG, Nurnberger JI Jr. Women with bipolar disorder: findings from the NIMH Genetics Initiative sample. Psychopharmacol Bull. 1998;34:239-243.

Bowden CL. Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry. 2004;65(suppl 15):21-24.

Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:392-400.

Calabrese JR, Hirschfeld RM, Reed M, et al. Impact of bipolar disorder on a US community sample. J Clin Psychiatry. 2003;64:425-432.

Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351-1360.

Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156:1417-1420.

Cochran SD. Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. J Consult Clin Psychol. 1984;52:873-878.

Colom F. The mechanism of action of psychotherapy. Bipolar Disord. 2002;4(suppl 1):102.

Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry. 2003;60:402-407.

Dantzler A, Osser DN. Algorithms for the pharmacotherapy of acute depression in patients with bipolar disorder. Psychiatr Ann. 1999;29:270-284.

Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry. 2000;61:179-184.

Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005;7:268-274.

Ferreri F, Agbokou C, Gauthier S. CMAJ. 2006;175:1545-1552.

Fossey MD, Otto MW, Yates WR, et al. Validity of the distinction between primary and secondary substance use disorder in patients with bipolar disorder: data from the first 1000 STEP-BD participants. Am J Addict. 2006;15:138-143.

Frances AJ, Kahn DA, Carpenter D, Docherty JP, Donovan SL. The Expert Consensus Guidelines for treating depression in bipolar disorder. J Clin Psychiatry. 1998;59(suppl 4):73-79.

Frank E, Kupfer DJ, Thase ME, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry. 2005;62:996-1004.

Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry. 2000;48:593-604.

Frye MA, Altshuler LL. Selection of initial treatment for bipolar disorder, manic phase. Mod Probl Pharmacopsychiatry. 1997;25:88-113.

Frye MA, Yatham LN, Calabrese JR, et al. Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. J Clin Psychiatry. 2006;67:1721-1728.

Gao K, Muzina D, Gajwani, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry. 2006;67:1327-1340.

Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry. 2000;61:804-808.

Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord. 2003;5:421-433.

Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry. 2001;62:565-569.

Ghaemi SN, Miller CJ, Berv DA, Klugman J, Rosenquist KJ, Pies RW. Sensitivity and specificity of a new bipolar spectrum diagnostic scale. J Affect Disord. 2005;84:273-277.

Ghaemi SN, Rosenquist KJ, Ko JY, Baldassano CF, Kontos NJ, Baldessarini RJ. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry. 2004;161:163-165.

Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GA. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161:1537-1547.

Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161:564-566.

Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry. 2002;63:985-991.

Goldberg JF, Garno JL. Development of posttraumatic stress disorder in adult bipolar patients with histories of severe childhood abuse. J Psychiatr Res. 2005;39:595-601.

Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry. 1999;60:733-740.

Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord. 2003;5:407-420.

Goodwin FK, Jamison KR. Manic Depressive Illness. Oxford University Press: New York, NY: 1990.

Gunderson JG, Weinberg I, Daversa MT, et al. Descriptive and longitudinal observations on the relationship of borderline personality disorder and bipolar disorder. Am J Psychiatry. 2006;163:1173-1178.

Hilty DM, Brady KT, Hales RE. A review of bipolar disorder among adults. Psychiatr Serv. 1999;50:201-213.

Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry. 2003;64:53-59.

Keck PE Jr, Welge JA, Strakowski SM, Arnold LM, McElroy SL. Placebo effect in randomized, controlled maintenance studies of patients with bipolar disorder. Biol Psychiatry. 2000;47:756-761.

Keck PE Jr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67:626-637.

Keck PE Jr, Strawn JR, McElroy SL. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. J Clin Psychiatry. 2006;67(suppl 1):8-15.

Keck PE Jr, Welge JA, Strakowski SM, Arnold LM, McElroy SL. Placebo effect in randomized, controlled maintenance studies of patients with bipolar disorder. Biol Psychiatry. 2000;47:756-761.

Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52:1048-1060.

Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6:368-373.

Kilbourne AM, Post EP, Bauer MS, et al. Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. J Affect Disord. 2007. Epub ahead of print.

Lam DH, Watkins ER, Hayward P, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry. 2003;60:145-152.

Leppik IE. Contemporary Diagnosis and Management of the Patient With Epilepsy. Newtown, PA: Handbooks in Health Care; 2001.

Levin FR, Hennessy G. Bipolar disorder and substance abuse. Biol Psychiatry. 2004;56:738-748.

Lewis L, Hoofnagle L. Patient perspectives on provider competence: a view from the Depression and Bipolar Support Alliance. Adm Policy Ment Health. 2005;32:497-503.

Mahmood T, Romans S, Silverstone T. Prevalence of migraine in bipolar disorder. J Affect Disord. 1999;52:239-241.

Maj M, Pirozzi R, Magliano L, Bartoli L. Agitated depression in bipolar I disorder: prevalence, phenomenology, and outcome. Am J Psychiatry. 2003;160:2134-2140.

Marangell LB. The importance of subsyndromal symptoms in bipolar disorder. J Clin Psychiatry. 2004;65(suppl 10):24-27.

Marcus R, et al. Presented at: 42nd Annual Meeting of the American College of Neuropsychopharmacology; December 2003; San Juan, Puerto Rico.

McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry. 2001;158:420-426.

McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63:207-213.

McIntyre RS, Konarski JZ, Soczynska JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv. 2006;57:1140-1144.

McIntyre RS, Konarski JZ, Yatham LN. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol. 2004;19:369-386.

McIntyre RS, Soczynska JK, Bottas A, Bordbar K, Konarski JZ, Kennedy SH. Anxiety disorders and bipolar disorder: a review. Bipolar Disord. 2006;8:665-676.

Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry. 2003;60:904-912.

Miklowitz DJ, Wisniewski SR, Miyahara S, Otto MW, Sachs GS. Perceived criticism from family members as a predictor of the one-year course of bipolar disorder. Psychiatry Res. 2005;136:101-111.

Müller HJ, Bottlender R, Grunze H, Strauss A, Wittmann J. Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression? J Affect Disord. 2001;67:141-146.

Muzina DJ, Calabrese JR. Recent placebo-controlled acute trials in bipolar depression: focus on methodology. Int J Neuropsychopharmacol. 2003;6:285-291.

Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158:906-912.

Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson’s disease for patients with major affective disorder: a register study. Acta Psychiatr Scand. 2001;104:380-386.

Physicians’ Desk Reference®. 59th ed. Montvale, NJ: Medical Economics Co; 2005.

Physicians’ Desk Reference®. 60th ed. Montvale, NJ: Medical Economics Co; 2006.

Pellock JM. Carbamazepine side effects in children and adults. Epilepsia. 1987;28(suppl 3):S64-S70.

Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;163:217-224.

Pollack MH, Simon NM, Fagiolini A, et al. Persistent posttraumatic stress disorder following September 11 in patients with bipolar disorder. J Clin Psychiatry. 2006;67:394-399.

Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189:124-131.

Poulin MJ, Cortese L, Williams R, Wine N, McIntyre RS. Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. Can J Psychiatry. 2005;50:555-562.

Rea MM, Tompson MC, Miklowitz DJ, Goldstein MJ, Hwang S, Mintz J. Family-focused treatment versus individual treatment for bipolar disorder: results of a randomized clinical trial. J Consult Clin Psychol. 2003;71:482-492.

Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511-2518.

Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care. 1998;36:1138-1161.

Sachs GS. Strategies for improving treatment of bipolar disorder: integration of measurement and management. Acta Psychiatr Scand Suppl. 2004;422:7-17.

Schiffer RB, Wineman NM, Weitkamp LR. Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry. 1986;143:94-95.

Scott J. Psychotherapy for bipolar disorders – efficacy and effectiveness. J Psychopharmacol. 2006;20:46-50.

Scott J, Colom F, Vieta E. A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders. Int J Neuropsychopharmacol. 2007;10:123-129.

Scott J, Gutierrez MJ. The current status of psychological treatments in bipolar disorders: a systematic review of relapse prevention. Bipolar Disord. 2004;6:498-503.

Singh A, Althoff R, Martineau RJ, Jacobson J. Pramipexole, ropinirole, and mania in Parkinson’s disease. Am J Psychiatry. 2005;162:814-815.

Strakowski SM, McElroy SL, Keck PW Jr, West SA. The co-occurrence of mania with medical and other psychiatric disorders. Int J Psychiatry Med. 1994;24:305-328.

Strakowski SM, Sax KW, McElroy SL, Keck PE Jr, Hawkins JM, West SA. Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. J Clin Psychiatry. 1998;59:465-471.

Strober M, Morrell W, Burroughs J, Lampert C, Danforth H, Freeman R. A family study of bipolar I disorder in adolescence. Early onset of symptoms linked to increased familial loading and lithium resistance. J Affect Disord. 1988;15:255-268.

Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66:870-886.

Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600-609.

Thomas P. The many forms of bipolar disorder: a modern look at an old illness. J Affect Disord. 2004;79(supp 1):S3-S8.

Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005;162:1281-1290.

Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079-1088.

Tohen M, Waternaux CM, Tsuang MT, Hunt AT. Four-year follow-up of twenty-four first-episode manic patients. J Affect Disord. 1990;19:79-86.

Weeke A, Juel K, Vaeth M. Cardiovascular death and manic-depressive psychosis. J Affect Disord. 1987;13:287-292.

Weiss RD, Greenfield SF, Najavits LM, et al. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry. 1998;59:172-174.

Yatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7(suppl 3):5-69.

Young LT. What exactly is a mood stabilizer? J Psychiatry Neurosci. 2004;29:87-88.

Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.

Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56:54-60.